Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues
Chinese Clinical Oncology · 2023
DOI: 10.21037/cco-22-108 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Chinese Clinical Oncology, 2023. Verfasst von Ioannis A Voutsadakis und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Sault Area Hospital, Sault Ste Marie, Ontario, Canada; Division of Clinical Sciences, …. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Adenocarcinoma, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 11-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Internal Medicine, Sault Area Hospital, Sault Ste Marie, Ontario, Canada; Division of Clinical Sciences, Northern Ontario School of Medicine, Sudbury, Ontario, Canada.
- Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausannne, Switzerland.
Zitieren
APA
Voutsadakis, I. A., & Digklia, A. (2023). Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues. Chinese Clinical Oncology. https://doi.org/10.21037/cco-22-108
Vancouver
Voutsadakis IA, Digklia A. Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues. Chinese Clinical Oncology. 2023. doi:10.21037/cco-22-108
BibTeX
@article{Voutsadakis2023,
author = {Voutsadakis, Ioannis A and Digklia, Antonia},
title = {Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues},
journal = {Chinese Clinical Oncology},
year = {2023},
doi = {10.21037/cco-22-108}
}
EUVIMED